2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6286 Immunoglobulin replacement practice patterns and infectious burden in patients with aggressive B-cell lymphoma receiving CD20xCD3 bispecific antibodies: Data from the ABC Consortium

Eiman Elmileik, MD, Preeti Nagalamadaka2, Thomas Ollila, MD3, Megan Melody, MD, MS4, Natalie S Grover, MD5, Megan M Herr, PhD6, Nour Nassour, MD7, Matthew J. Cortese, MD, MPH8, Jonathon B. Cohen, MD, MS9, Hiffsa Taj, MD, MBBS10, Natalie Jo Hawes, BSN11, Adit Dharia, MD12, Max Farber Kelsten, MD13, Nicole Altomare, MD14, Colin J. Thomas, MD15, Brian Hess, MD16, James A Davis, PharmD, BCOP17, Joanna M Rhodes, MD, MSCE18, Adam Kidwell, MD19, Tamara K Moyo, MD,PhD20, Lindsey Fitzgerald, MD21, Yasmin H Karimi, MD22, Omar Elghawy, MD23, Nikesh N. Shah, MD24, Daniel A. Kerr, MD, PhD25, Deborah Stephens, DO26, Daniel Antonio, MPH27, Jonathan Moreira, MD28, Shuo Ma, MD29, Jane N Winter, MD30, Leo Gordon, MD31, Nirav N. Shah, MD, MS32, Narendranath Epperla, MD, MS, FACP33, Reem Karmali, MD34, Matthew Matasar, MD35, Ari R. Pelcovits, MD36
1 Brown Univeristy, Providence, Rhode Island, United States
2 Brown Univeristy, Providence, Rhode Island, United States
3 Brown Univeristy, Providence, Rhode Island, United States
4 Tampa General Hospital Cancer Institute, Tampa, United States
5 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
8 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
9 Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
10 Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States
11 Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States
12 HCA Florida Oak Hill Hospital/ USF Morsani College of Medicine, Tampa, Florida, United States
13 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
14 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
15 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
16 Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States
17 Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States
18 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
19 Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States
20 Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, United States
21 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
22 Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, United States
23 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
24 Tampa General Hospital Cancer Institute, Tampa, United States
25 Tampa General Hospital Cancer Institute, Tampa, United States
26 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
27 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
28 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
29 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
30 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
31 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
32 Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States
33 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
34 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
35 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
36 Brown Univeristy, Providence, Rhode Island, United States

Background:
CD20xCD3 bispecific antibodies (BsAbs) are standard of care therapy for relapsed/refractory aggressive B-cell lymphomas. These agents cause sustained B-cell aplasia and hypogammaglobulinemia, with infection a leading cause of non-relapse mortality. Guidance on intravenous immunoglobulin (IVIG) use in this population is limited. There exists a knowledge gap on the use of IVIG in clinical practice, as well as recommendations for best practice. We sought to describe IVIG delivery in patients with aggressive B-cell lymphomas receiving BsAbs in a large multicenter population.  

Methods: 
We analyzed adults with aggressive B-cell lymphomas treated with CD20xCD3 BsAbs across 11 US centers. Infectious events within 6 months of BsAb initiation were captured. Variables included receipt of IVIG at any point during therapy, treatment type (monotherapy vs. BsAb-based combination therapy), infection type and severity, prior CAR T-cell therapy, survival status, and cause of death. The primary endpoint was prevalence and center-level variation in IVIG use; secondary endpoints were all-grade infection incidence by type and infection-attributed death, stratified by IVIG exposure. Analyses were complete-case, with denominators reported per estimate. IVIG was captured as an ever/never exposure without IgG levels or timing, so primary and secondary prophylaxis cannot be distinguished. Categorical variables were compared using Pearson chi-square, with Fisher exact test where expected cell counts were <5.

Results: 
Among 324 patients who initiated BsAb between 2019 and 2025, IVIG status was available for 317, of whom 158 (49.8%) received BsAb monotherapy and 159 (50.2%) received combination therapy. Overall, 65 patients (20.5%) received IVIG and 252 (79.5%) received none. Use differed across the 11 centers (chi-square=28.30, df=10, p=0.0016) but not by treatment type: 23.9% of combination-treated vs. 17.1% of monotherapy-treated patients (OR 1.52, 95% CI 0.88-2.65; p=0.13). 

Among 315 patients with evaluable infection data (64 IVIG, 251 non-IVIG), all-grade infection occurred in 96.9% of IVIG recipients vs. 80.5% of non-recipients (RR 1.20, 95% CI 1.12-1.30; p=0.0015). Infection type was documented in 91 of 264 infected patients: 56.0% involved a bacterial pathogen, 39.6% were viral only, and 4.4% fungal. Severity was documented in 80 infected patients with known IVIG status: 43 (53.8%) required intravenous antimicrobials or hospitalization, 23 (28.8%) were managed with oral antimicrobials as outpatients, and 14 (17.5%) required no intervention. Hospitalization-level severity occurred in 63.0% (17/27) of IVIG recipients vs. 49.1% (26/53) of non-recipients (RR 1.28, 95% CI 0.86-1.91; p=0.22). 

Infection occurred in 94.4% (118/125) of patients with prior CAR-T vs. 76.9% (150/195) without (RR 1.23, 95% CI 1.12-1.34; p<0.0001). Among those with IVIG data, IVIG was received by 24.6% (30/122) with prior CAR-T vs. 17.1% (33/193) without (RR 1.44, 95% CI 0.93-2.23; p=0.11).

Survival data were available for 319 patients: 180 (56.4%) were alive, 71 (22.3%) died of lymphoma, 49 (15.4%) died of other causes, and 19 (6.0%) died of infection. Among 312 patients with both IVIG and outcome data, infection-attributed death occurred in 10.9% of IVIG recipients vs. 4.4% of non-recipients (RR 2.47, 95% CI 1.00-6.11; p=0.07).

Conclusion:
IVIG was utilized in only a minority of patients receiving BsAbs for aggressive B-cell lymphomas, despite most patients developing infectious complications. Use varied significantly across centers, suggesting that immunoglobulin support is determined more by institutional practice than by patient or regimen-level risk. IVIG use remained low (24.6%) even among patients with prior CAR T-cell therapy, in whom infection occurred in 94.4%, a level of use that appears discordant with the observed infectious risk. Where captured, infections were predominantly bacterial and over half required intravenous antimicrobials or hospitalization, suggesting a burden not confined to mild viral events. The higher infection incidence among IVIG recipients suggests that it is preferentially used as secondary rather than primary prophylaxis.

These findings demonstrate substantial practice heterogeneity and a high infectious burden in a population for whom optimal IVIG use is undefined. Prospective studies incorporating IgG levels, timing relative to BsAb administration, and other anti-infective strategies are needed to inform IVIG guidance.

Eiman Elmileik, MD: No relevant conflicts of interest to declare.